The European Pharmaceutical Strategy: A patient-centred and future-proof framework?

Update: 2021-09-23

Description

SOUNDS OF SCIENCE - EPISODE 3

A lot is currently happening in terms of health policy and discussions around how to organise our healthcare systems. The European Commission's proposal for a Pharmaceutical Strategy certainly holds a lot of potential, however, what can be done to make this initiative a real catalyst for a patient-centred and future-proof framework?

A transparent and dynamic Q&A with EUCOPE in-house experts Victor Maertens and Matias Olsen.

Comments

In Channel

The Revision of the General Pharmaceutical Legislation: European Parliament Reports

2024-05-0643:21

Real-World Evidence (RWE): The need for a multi-stakeholder approach

2023-08-1851:03

Rare Reflections: Impact of the OMP revision on rare disease companies in Europe

2023-07-1140:19

MDR/IVDR: Recent changes and their implications for EU medical device companies

2023-04-1034:27

Trans-Atlantic Innovation : Building bridges between the EU and US life sciences industry

2023-03-1344:27

Rare Disease Day 2023: Improving equitable access and diagnosis for people living with a rare disease

2023-02-2247:51

The new EU HTA Procedure: Getting it right to improve patients' access to innovative therapies

2023-01-3020:28

2022 Year in Review: Perspectives & Resolutions from the EUCOPE Policy Team

2022-12-2131:29

Launch Conditionality: The Impact on Small and Mid-Sized Companies

2022-12-1637:59

Advanced Therapy Medicinal Products (ATMPs): How they will be affected by the General Pharmaceutical Legislation

2022-10-1338:37

Ensuring a robust European Health Data Space (EHDS): Working to create a fit-for-purpose regulatory framework

2022-09-1923:14

Unmet Medical Needs (UMN): Towards a new understanding with a focus on underserved areas

2022-07-1834:22

Overcoming Barriers: Improving Access for Rare Disease Patients through Cross-Border Healthcare

2022-06-0629:44

Increasing Access to Genomic Testing in Europe: The role of national genomics initiatives in increasing uptake of Advanced Diagnostics

2022-05-1025:31

What's next for EU Rare Disease Legislation? Its potential implications for patients and pharma entrepreneurs